COMP <GO>
NVAX vs TSHA // RETURN ON INVESTED CAPITAL (ROIC)
Novavax Inc. (NASDAQ) VS. Taysha Gene Therapies Inc. (NASDAQ) • 15-METRIC TALLY: NVAX 7
— TSHA 2
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: NVAX
LAST: $9.53 (-5.46%) • MKT CAP: $1.66B
roic
85.00%
LAST: $4.00 (-3.15%) • MKT CAP: $1.35B
roic
-35.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NVAX VS. TSHA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NVAX | TSHA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 93.50% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 85.00% | -35.00% | +120.00 | NVAX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -14.17% | -6.82% | -7.35 | TSHA | /fcf-yield <GO> |
| Operating Margin | 40.30% | -60.00% | +100.30 | NVAX | /operating-margins <GO> |
| Net Profit Margin | 39.20% | -60.00% | +99.20 | NVAX | /net-margins <GO> |
| Revenue Growth (YoY) | 64.70% | 17.30% | +47.40 | NVAX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.67 | -5.47 | TSHA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 4/9 | +1.00 | NVAX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.3 | 44.2 | +1.10 | NVAX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 3.5x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.66B | $1.35B | $317.0M | NVAX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NVAX REV | TSHA REV | NVAX GROSS % | TSHA GROSS % | NVAX FCF | TSHA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.12B | $9.8M | 93.5% | — | -$244.6M | -$93.8M |
| FY 2024 | $682.2M | $8.3M | 70.3% | — | -$87.3M | -$81.6M |
| FY 2023 | $983.7M | $15.5M | — | — | -$714.0M | -$73.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NVAX // BETA —
TSHA // BETA —